Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Regulatory press release

Change in number of shares and votes in Episurf Medical

Episurf Medical
Download the release

Episurf Medical AB (Nasdaq: EPIS B) has, pursuant to previously announced information, carried out a rights issue of units consisting of shares of series B and warrants of series TO14 B. The rights issue has resulted in a change in the number of shares and votes in the company. Through the rights issue, the number of shares has increased by 979,597,038 shares of series B and the number of votes has increased by 979,597,038.

Furthermore, the company has, pursuant to previously announced information, carried out a set-off issue of units consisting of shares of series B and warrants of series TO14 B directed to certain guarantors in the rights issue. The set-off issue has resulted in a change in the number of shares and votes in the company. Through the set-off issue, the number of shares has increased by 27,099,648 shares of series B and the number of votes has increased by 27,099,648.

As a consequence of the above-mentioned changes, the total number of shares amounts to 1,659,761,378, of which 473,357 are shares of series A and 1,659,288,021 are shares of series B, and the total number of votes amounts to 1,660,708,092.

For more information, please contact:

Pål Ryfors, CEO and interim CFO, Episurf Medical
Tel: +46 709 62 36 69
Email: pal.ryfors@episurf.com

This information is information that Episurf Medical AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person set out above, at 12.15 CEST on 30 September 2025.

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical's Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical's μiFidelity® system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: www.episurf.com.

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.